General Practitioners

• Infectious Diseases
  Over the last decade, AVX was awarded four multi-million dollar biodefense grants, further validating the utility of the alphavaccine vector technology in this arena. We have worked in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to assess the performance of these vaccine candidates in animal studies in high-containment laboratories. In the face of a credible threat, emergency stockpiles of such vaccines could be manufactured for government-directed use. Products based on these candidates can be approved for widespread use based on human safety and the animal rule.
• Immunizations
  Lack of Inhibition by Anti-Vector Immunity – A very significant alphavaccine advantage over many competing vector systems is the absence of significant pre-existing anti-vector immunity in human populations, since most humans have never been exposed to VEE virus. Furthermore, preclinical animal studies have demonstrated that the anti-vector immunity that develops after initial vaccination with VRP (or even vaccination to VEE virus itself) does not significantly hinder efficacy in repeated or simultaneous vaccinations with VRP. This is in direct contrast to the experience with most virus vectors. Thus, it is possible to efficiently boost immune responses using the same VRP vaccine used to prime, and heterologous prime-boost vaccination regimens that have significantly improved the response to some vector systems have not been necessary with alphavaccines. In addition, a universal vaccination indication for a vector such as adenovirus-5 (Ad5) would effectively eliminate that vector as a vaccine solution for any other disease, or for a disease such as influenza where annual vaccinations are needed.

Gynecologists

• Pregnancy

Internists

• Colon Cancer
  Ability to Break Tolerance against Self Antigens in Cancer Models – An essential prerequisite for any vaccine approach in a tumor immunotherapeutic setting is the ability to break tolerance to tumor-associated antigens that the immune system does not normally recognize, allowing cancer cells to multiply and spread throughout the body. Alphavaccines have been shown to break immunological tolerance in several stringent tumor challenge models, and now in humans against CEA in patients with Stage IV CEA+ colon cancer.
• Prostate Cancer
  Four alphavaccine candidates, targeting human cytomegalovirus, influenza A virus, prostate cancer and HIV-1, have been evaluated in five Phase 1 clinical trials. More recently, AVX has focused its efforts in an additional three clinical trials with two additional vaccine candidates (one in breast cancer, two in GI cancers) in the development of immunotherapeutic vaccines for the treatment of various cancers. From these latter efforts, AVX has successfully progressed the development of its proprietary alphavaccine RNA particletechnology, to create new, potentially first-in-class, vaccines that engage the patient’s immune system both to recognize and fight off various cancers.

Dermatologists

• Skin Cancer
  Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity click here >>